Pentixapharm Unveils New Clinical Development Strategy

Pentixapharm Holding AG, a biopharmaceutical company specializing in radiopharmaceuticals, announced a strategic shift in its clinical development approach. The company plans to focus its efforts on theranostic precision oncology, targeting the CXCR4 chemokine receptor. This decision comes after a management review and aims to enhance the value of its CXCR4 assets.

The PTF301 diagnostic trial in Marginal Zone Lymphoma will be discontinued due to low patient recruitment. Instead, new trials for hematologic malignancies and bladder cancer are being prepared. Additionally, the PTT101 trial in CNS Lymphoma will now be part of a basket program aimed at evaluating CXCR4-targeted therapies' efficacy across various indications.

Outside oncology, Pentixapharm continues developing a non-invasive diagnostic for primary aldosteronism. This strategic refocus might lead to significant improvements in treatments for hematologic malignancies.